What was 3B Blackbio DX's revenue in Q3 FY26?

3B Blackbio DX reported revenue of ₹50 Cr in Q3 FY26, a +11.8% change year-over-year.

Did 3B Blackbio DX management deliver on previous promises?

Scorecard data is being built as historical quarters are processed.

3B Blackbio DX Q3 FY26 Research Workspace: Revenue ₹50 Cr (+11.8%)

Q: What guidance did 3B Blackbio DX management give?

Full-year revenue growth 10-15%: Management expects overall top-line growth of 10-15% for FY26, excluding one-off items.

Revenue ₹50 Cr +11.8%

EBITDA —

PAT ₹22 Cr

EBITDA Margin 43.14%

Duration 58 min

Read Time 1 min read

✓ Verified against BSE filing

2-Minute Summary

✦ AI-Generated from Full Transcript

3B Blackbio reported 9-month revenue of ₹99.06 crore, up 11.8% YoY (or ~20% excluding seasonal flu spikes). Excluding a one-off HAT contract of ~₹8.8 crore, core growth was modest. Management guided full-year top-line growth of 10-15% and export growth of 15-20%, with EBITDA margin likely compressed due to one-time M&A expenses. The company maintains a 12-15% market share in the Indian open-system molecular diagnostics market (TAM ₹400-500 crore). Key growth drivers include the Chorus acquisition (lateral flow/AMR), UK subsidiary expansion, and upcoming US FDA filings for Chorus products. Risks include intensifying competition from players entering high-margin molecular diagnostics, lumpy HAT contract sunsetting in 2 years, and slow NGS adoption. The company is actively scouting for acquisitions with ~₹130-140 crore earmarked.

Risks4 trackedTranscriptfull text

Research workspace

Focused Modules

⚖Claim Ledger 73% answered

Did management answer the analysts?

12 analyst questions audited, 1 evaded or deflected.

View Claim Ledger →

!Risks 4 risks

Risk Intelligence

Increasing competition in molecular diagnostics

View Risks →

≡Transcript Full text

Call Transcript

Full transcript text is available on this route.

Read Transcript →

Quarter Snapshot

Market share in Indian open-system molecular diagnostics 12-15%

flat

Company estimates its share of the ₹400-500 crore addressable market.

Export growth rate (9M FY26) 26%

+26% YoY

Exports grew 26% in 9M, driven by UK subsidiary and PCR Europe.

HAT contract revenue (Q3 FY26) ₹8.8 crore

one-off

One-off revenue from WHO HAT contract; expected to continue at ~$1.5M/year for 2 more years.

Number of countries exported to 70

flat

Company exports to 70 countries through PCR Europe and other channels.

Fast read

Guidance and risk preview

Top guidance Full-year revenue growth 10-15%

Management expects overall top-line growth of 10-15% for FY26, excluding one-off items.

Top risk Increasing competition in molecular diagnostics

New entrants from biochemistry/ELISA are entering molecular diagnostics due to high margins, pressuring pricing and market share.